Aeglea BioTherapeutics Inc. (NASDAQ: AGLE) stock closed at 1.54 per share at the end of the most recent trading day (a 7.69% change compared to the prior day closing price) with a volume of 128.10K shares and market capitalization of 91.76M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 87 people. Aeglea BioTherapeutics Inc. CEO is Anthony G. Quinn.

The one-year performance of Aeglea BioTherapeutics Inc. stock is -79.19%, while year-to-date (YTD) performance is -67.58%. AGLE stock has a five-year performance of -74.92%. Its 52-week range is between 1.29 and 8.5, which gives AGLE stock a 52-week price range ratio of 2.91%

Aeglea BioTherapeutics Inc. currently has a PE ratio of -1.30, a price-to-book (PB) ratio of 1.37, a price-to-sale (PS) ratio of 4.35, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -58.37%, a ROC of -73.74% and a ROE of -77.69%. The company’s profit margin is -%, its EBITDA margin is -349.50%, and its revenue ttm is $20.10 Million , which makes it $0.33 revenue per share.

Of the last four earnings reports from Aeglea BioTherapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.35 for the next earnings report. Aeglea BioTherapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Aeglea BioTherapeutics Inc. is Strong Buy (1), with a target price of $10.25, which is +583.33% compared to the current price. The earnings rating for Aeglea BioTherapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aeglea BioTherapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aeglea BioTherapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 7.93, ATR14 : 0.18, CCI20 : -10.35, Chaikin Money Flow : -0.10, MACD : -0.20, Money Flow Index : 23.89, ROC : 6.94, RSI : 42.65, STOCH (14,3) : 73.53, STOCH RSI : 1.00, UO : 48.10, Williams %R : -26.47), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aeglea BioTherapeutics Inc. in the last 12-months were: Anthony G. Quinn (Buy at a value of $667 620), Armen Shanafelt (Buy at a value of $549 692), Jonathan Alspaugh (Buy at a value of $604 660)